^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR mutation + RET fusion

    i
    Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1, EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956; 5979
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1year
    Pralsetinib in acquired RET fusion positive advanced non-small cell lung cancer patients after resistance to EGFR/ALK-TKI: a China multi-center, real-world data(RWD) analysis (ELCC 2023)
    Pralsetinib and EGFR-TKI combination therapy was generally well tolerated, with AEs consistent with known profile of the two drugs. Conclusions Pralsetinib-based therapy may be a potential strategy to overcome the acquired RET-fusion after resistance of EGFR/ALK-TKIs.
    Clinical • Real-world evidence • IO biomarker • Real-world • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • KIF5B (Kinesin Family Member 5B) • CCDC6 (Coiled-Coil Domain Containing 6) • NCOA4 (Nuclear Receptor Coactivator 4)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • RET fusion • ALK fusion • RET mutation • NCOA4-RET fusion • EGFR mutation + RET fusion • RET positive
    |
    Gavreto (pralsetinib)
    almost2years
    RET Fusions as Primary Oncogenic Drivers and Secondary Acquired Resistance to EGFR TKI in a Large Cohort of Non-Small-Cell Lung Cancers (IASLC-WCLC 2022)
    Our study systematically evaluated the genetic landscape underlying RET fusions as a rare driver gene and provide important insights into secondary resistance to EGFR TKIs in Chinese NSCLCs, which will be important considerations in improving the efficacy and clinical outcome of existing RET inhibitors and facilitating the development of new therapeutics.
    Preclinical
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • RET (Ret Proto-Oncogene) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • KIF5B (Kinesin Family Member 5B) • MDM2 (E3 ubiquitin protein ligase) • CCDC6 (Coiled-Coil Domain Containing 6) • SMAD4 (SMAD family member 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NCOA4 (Nuclear Receptor Coactivator 4)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • RET fusion • RET mutation • KIF5B-RET fusion • CCDC6-RET fusion • CDKN2A mutation • NCOA4-RET fusion • EGFR mutation + RET fusion • EGFR fusion • RET positive
    |
    Tagrisso (osimertinib)